FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897599786> ?p ?o ?g. }

• W2897599786 endingPage "2567" @default.
• W2897599786 startingPage "2554" @default.
• W2897599786 abstract "Abstract Receptor tyrosine kinase (RTK)-dependent signaling has been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL) of childhood. However, the RTK-dependent signaling state and its interpretation with regard to biological behavior are often elusive. To decipher signaling circuits that link RTK activity with biological output in vivo, we established patient-derived xenograft ALL (PDX-ALL) models with dependencies on fms-like tyrosine kinase 3 (FLT3) and platelet-derived growth factor receptor β (PDGFRB), which were interrogated by phosphoproteomics using iTRAQ mass spectrometry. Signaling circuits were determined by receptor type and cellular context with few generic features, among which we identified group I p21-activated kinases (PAKs) as potential therapeutic targets. Growth factor stimulation markedly increased catalytic activities of PAK1 and PAK2. RNA interference (RNAi)-mediated or pharmacological inhibition of PAKs using allosteric or adenosine triphosphate (ATP)-competitive compounds attenuated cell growth and increased apoptosis in vitro. Notably, PAK1- or PAK2-directed RNAi enhanced the antiproliferative effects of the type III RTK and protein kinase C inhibitor midostaurin. Treatment of FLT3- or PDGFRB-dependent ALLs with ATP-competitive PAK inhibitors markedly decreased catalytic activities of both PAK isoforms. In FLT3-driven ALL, this effect was augmented by coadministration of midostaurin resulting in synergistic effects on growth inhibition and apoptosis. Finally, combined treatment of FLT3D835H PDX-ALL with the ATP-competitive group I PAK inhibitor FRAX486 and midostaurin in vivo significantly prolonged leukemia progression-free survival compared with midostaurin monotherapy or control. Our study establishes PAKs as potential downstream targets in RTK-dependent ALL of childhood, the inhibition of which might help prevent the selection or acquisition of resistance mutations toward tyrosine kinase inhibitors." @default.
• W2897599786 created "2018-10-26" @default.
• W2897599786 creator A5005256757 @default.
• W2897599786 creator A5009948430 @default.
• W2897599786 creator A5014597115 @default.
• W2897599786 creator A5017516640 @default.
• W2897599786 creator A5023752156 @default.
• W2897599786 creator A5024275910 @default.
• W2897599786 creator A5026797793 @default.
• W2897599786 creator A5034079462 @default.
• W2897599786 creator A5042823383 @default.
• W2897599786 creator A5049501883 @default.
• W2897599786 creator A5049888549 @default.
• W2897599786 creator A5052614189 @default.
• W2897599786 creator A5056036658 @default.
• W2897599786 creator A5059147280 @default.
• W2897599786 creator A5061922466 @default.
• W2897599786 creator A5064540049 @default.
• W2897599786 creator A5074106380 @default.
• W2897599786 creator A5077524772 @default.
• W2897599786 creator A5078708602 @default.
• W2897599786 creator A5082541553 @default.
• W2897599786 creator A5089507510 @default.
• W2897599786 creator A5090389444 @default.
• W2897599786 date "2018-10-09" @default.
• W2897599786 modified "2023-10-15" @default.
• W2897599786 title "Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL" @default.
• W2897599786 cites W152196492 @default.
• W2897599786 cites W1639582946 @default.
• W2897599786 cites W1964653803 @default.
• W2897599786 cites W1965336646 @default.
• W2897599786 cites W1966803171 @default.
• W2897599786 cites W1980516263 @default.
• W2897599786 cites W1981225314 @default.
• W2897599786 cites W1984227596 @default.
• W2897599786 cites W1994568187 @default.
• W2897599786 cites W2014644181 @default.
• W2897599786 cites W2032211985 @default.
• W2897599786 cites W2032554800 @default.
• W2897599786 cites W2036161897 @default.
• W2897599786 cites W2047302466 @default.
• W2897599786 cites W2047398915 @default.
• W2897599786 cites W2047403065 @default.
• W2897599786 cites W2049069390 @default.
• W2897599786 cites W2052795297 @default.
• W2897599786 cites W2053785734 @default.
• W2897599786 cites W2060605982 @default.
• W2897599786 cites W2071274119 @default.
• W2897599786 cites W2074677800 @default.
• W2897599786 cites W2082286876 @default.
• W2897599786 cites W2085538774 @default.
• W2897599786 cites W2093051682 @default.
• W2897599786 cites W2103894337 @default.
• W2897599786 cites W2128296734 @default.
• W2897599786 cites W2136708374 @default.
• W2897599786 cites W2148202982 @default.
• W2897599786 cites W2155087173 @default.
• W2897599786 cites W2155228605 @default.
• W2897599786 cites W2159473577 @default.
• W2897599786 cites W2166969231 @default.
• W2897599786 cites W2168339088 @default.
• W2897599786 cites W2344726805 @default.
• W2897599786 cites W2554498999 @default.
• W2897599786 cites W2715749014 @default.
• W2897599786 cites W2759091821 @default.
• W2897599786 cites W4296816736 @default.
• W2897599786 doi "https://doi.org/10.1182/bloodadvances.2018020693" @default.
• W2897599786 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6177654" @default.
• W2897599786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30301811" @default.
• W2897599786 hasPublicationYear "2018" @default.
• W2897599786 type Work @default.
• W2897599786 sameAs 2897599786 @default.
• W2897599786 citedByCount "14" @default.
• W2897599786 countsByYear W28975997862019 @default.
• W2897599786 countsByYear W28975997862020 @default.
• W2897599786 countsByYear W28975997862021 @default.
• W2897599786 countsByYear W28975997862022 @default.
• W2897599786 countsByYear W28975997862023 @default.
• W2897599786 crossrefType "journal-article" @default.
• W2897599786 hasAuthorship W2897599786A5005256757 @default.
• W2897599786 hasAuthorship W2897599786A5009948430 @default.
• W2897599786 hasAuthorship W2897599786A5014597115 @default.
• W2897599786 hasAuthorship W2897599786A5017516640 @default.
• W2897599786 hasAuthorship W2897599786A5023752156 @default.
• W2897599786 hasAuthorship W2897599786A5024275910 @default.
• W2897599786 hasAuthorship W2897599786A5026797793 @default.
• W2897599786 hasAuthorship W2897599786A5034079462 @default.
• W2897599786 hasAuthorship W2897599786A5042823383 @default.
• W2897599786 hasAuthorship W2897599786A5049501883 @default.
• W2897599786 hasAuthorship W2897599786A5049888549 @default.
• W2897599786 hasAuthorship W2897599786A5052614189 @default.
• W2897599786 hasAuthorship W2897599786A5056036658 @default.
• W2897599786 hasAuthorship W2897599786A5059147280 @default.
• W2897599786 hasAuthorship W2897599786A5061922466 @default.
• W2897599786 hasAuthorship W2897599786A5064540049 @default.
• W2897599786 hasAuthorship W2897599786A5074106380 @default.
• W2897599786 hasAuthorship W2897599786A5077524772 @default.
• W2897599786 hasAuthorship W2897599786A5078708602 @default.

• next